Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study

PURPOSE: Esophageal squamous cell carcinoma is associated with high morbidity and mortality rate for which radiotherapy is the main treatment modality. Niraparib, a Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) was previously reported to confer radiosensitivity in different malignancies includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yuzhong, Huang, Wei, Du, Feng, Yin, Xiaoyang, Feng, Lei, Li, Baosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283188/
https://www.ncbi.nlm.nih.gov/pubmed/35364771
http://dx.doi.org/10.1007/s12094-022-02818-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283188/
https://www.ncbi.nlm.nih.gov/pubmed/35364771
http://dx.doi.org/10.1007/s12094-022-02818-7

Ejemplares similares